Results 151 to 160 of about 21,002 (228)

Correction: Health technology assessment of surgical robots: a mini-review of a rapidly evolving field. [PDF]

Front Public Health
Zhang T, Zhong Y, Zeng J, Liu GG.
europepmc   +1 more source

Translation and cross-cultural adaptation of the parental version of Type 1 Diabetes and Life (T1DAL): a US patient-reported outcome measurement into Danish following ISPOR guidelines. [PDF]

BMJ Open
Lind N, DeCosta P, Svensson J.
europepmc   +1 more source

Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy. [PDF]

Pharmacoecon Open
Salcedo J, Hill-McManus D, Hardern C, Opeifa O, Viti R, Siviero L, Roscini AS, Di Martino G.   +7 more
europepmc   +1 more source

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. [PDF]

Pharmacoeconomics
Fernández Coves A, Scholte M, Emerson J, Wolff R, Abu-Zahra T, Chen J, McDermott K, Armstrong N, Joore M, Witlox W.   +9 more
europepmc   +1 more source

Health Utility Values Measured by EQ-5D in Breast Cancer From Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis Protocol. [PDF]

Pharmacoecon Open
Tay LJ, Ong SC, Tay LX.
europepmc   +1 more source

What is the Value of Developing an HTA Process? [PDF]

Pharmacoeconomics
Murphy P, Walker S, Putri S, Sculpher M, Griffin S.   +4 more
europepmc   +1 more source

Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs.

JAMA Health Forum
Hwang TJ, Tibau A, Kesselheim AS, Vokinger KN.   +3 more
europepmc   +1 more source

Inhaled Levodopa for the Management of OFF Episodes in Parkinson's Disease: A Cost-Effectiveness Analysis. [PDF]

Pharmacoeconomics
Evans D, Mistry C, Knight H, Shah R, Guerra-Primo L, Gadeberg HC, Perni S, Clarke W, Brown J, Pietsch GA, Silas U, Carroll C.   +11 more
europepmc   +1 more source

Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology. [PDF]

Pharmacoeconomics
Reddy B, Telford C, Ambavane A, Mahajan S, Caro JJ.   +4 more
europepmc   +1 more source

Comparative risk of nonvertebral fractures associated with oral anticoagulants in patients with venous thromboembolism. [PDF]

Am J Epidemiol
Zeng Z, Bea S, Sreedhara SK, Bykov K.
europepmc   +1 more source